Latest Topiramate Stories

MOUNTAIN VIEW, Calif., Dec. 7, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) announced that an oral presentation was given at the International Diabetes Federation's World Diabetes Congress, in Dubai, United Arab Emirates today. The presentation highlighted excess weight loss, improvement of glycemic parameters in diabetic patients with a BMI>35 and effects on diabetes status. This is the first World Diabetes Congress to be organized in the Middle East and North Africa Region...

<font size="2" face="Arial"> </font> MAPLE GROVE, Minn., Dec. 5, 2011 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced the presentation of Phase 1 data showing that once-daily administration of USL255, a proprietary, extended-release (ER) formulation of the epilepsy medication topiramate, demonstrated linear dose-proportionality and, when compared to immediate-release (IR) topiramate administered twice-daily, an improved...

MOUNTAIN VIEW, Calif., Dec. 5, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts were presented over the weekend at the 2011 European Society of Sexual Medicine (ESSM) Meeting in Milan, Italy. The ESSM is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in Europe. The specific abstracts that were presented on December 3rd, 2011 include: A moderated poster presentation by...

MOUNTAIN VIEW, Calif., Dec. 1, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 Deutsche Bank BioFEST Conference. The VIVUS presentation will take place at the Four Seasons Hotel, Boston, MA on Tuesday, December 6, 2011 at 10:20 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS VIVUS is a...

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV. Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results...

MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ -- Highlights from Avanafil Development Program Include: Early onset of action observed in placebo-controlled trialsComparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafilSafety and efficacy in post-prostatectomy populationVIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The SMSNA is...

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that results from the 56-week EQUIP study were published in Obesity, the peer-reviewed journal of The Obesity Society. The EQUIP study evaluated the efficacy and safety of the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 kg/m(2)) patients across 91 sites in the US. In addition to average weight loss of 14.4% of initial body weight among those who completed the study at the top...

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the New Drug Application (NDA) for Qnexa® to treat obesity. The company resubmitted the NDA on October 17, 2011. The agency assigned a six-month, or class 2, review classification to the NDA, establishing April 17, 2012, as the Prescription Drug User Fee Act (PDUFA) target date. The FDA indicated that an...

The Consumer Justice Foundation, a for-profit corporation that is staffed by a team of professional consumer advocates whose mission is to alert the public of potential dangers associated with the use of prescription medications and whose URL can be found at http://www.topamaxbirthinjury.com, hereby alerts the public to the posting of third-quarter sales of Topamax by Johnson & Johnson, the manufacturer of this medication. (PRWEB) October 27, 2011 The Consumer Justice Foundation, a...

SILVER SPRING, Md., Oct. 24, 2011 /PRNewswire-USNewswire/ -- On Oct. 21, the U.S. Food and Drug Administration approved Onfi tablets (clobazam) for use as an adjunctive (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older. As Onfi is intended to treat a disease or condition that affects fewer than 200,000 people in the United States, it was granted orphan drug designation by the FDA. (Logo:...